Spots Global Cancer Trial Database for hodgkin lymphoma
Every month we try and update this database with for hodgkin lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma | NCT01569204 | Hodgkin Lymphom... | Etoposide Cyclophosphamid... Doxorubicin Prednisone Procarbazine Dexamethasone Dacarbazine Brentuximab Ved... | 18 Years - 60 Years | University of Cologne | |
| Hybrid SPECT/CTCA for the Assessment of the Presence and Hemodynamic Significance of CAD in Asymptomatic Patients. | NCT01239446 | Hodgkin Lymphom... | Not relevant (t... | 18 Years - 65 Years | Rambam Health Care Campus | |
| CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant | NCT06059391 | Acute Lymphobla... Acute Myeloid L... Chronic Lymphoc... Chronic Myeloid... Hematopoietic a... Hodgkin Lymphom... Myelodysplastic... Myelofibrosis Myeloproliferat... Non-Hodgkin Lym... | Allogeneic Hema... Biospecimen Col... Granulocyte Col... Hematopoietic C... Multi-peptide C... Pheresis Placebo Adminis... Stem Cell Mobil... | 18 Years - | City of Hope Medical Center | |
| First in Human, Dose Escalation, Dose Expansion Study of AUR105 | NCT05605119 | Solid Tumor, Ad... Non-hodgkin Lym... Hodgkin Lymphom... | AUR105 | 18 Years - 99 Years | Aurigene Discovery Technologies Limited | |
| PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma | NCT05922904 | Hodgkin Lymphom... | Brentuximab ved... Doxorubicin Hyd... Pembrolizumab Dacarbazine | 18 Years - | M.D. Anderson Cancer Center | |
| Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients | NCT02098512 | Hodgkin Lymphom... | Brentuximab Ved... Allogeneic Stem... Reduced Intensi... | - 45 Years | New York Medical College | |
| BV After Allogeneic Hematopoietic Stem Cell Transplantation | NCT03540849 | Hodgkin Lymphom... | Brentuximab Ved... | 18 Years - 65 Years | University Hospital, Caen | |
| Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer | NCT05400122 | Colorectal Canc... Hematologic Mal... Rectum Cancer Acute Myeloid L... Myelodysplastic... Acute Lymphobla... Chronic Myeloid... Chronic Lymphoc... Hodgkin Lymphom... Non Hodgkin Lym... Myeloproliferat... Plasma Cell Mye... | Vactosertib Fludarabine Pho... Cyclophosphamid... IL-2 Natural Killer ... | 18 Years - | Case Comprehensive Cancer Center | |
| Immunogenicity of COVID-19 Vaccination in Autologous HSCT or CAR-T Cells Recipients | NCT05597761 | COVID-19 Non Hodgkin Lym... Hodgkin Lymphom... | 18 Years - | University of Cologne | ||
| Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma | NCT02429375 | Hodgkin Lymphom... | Mocetinostat Pl... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Treatment With Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkins Lymphoma | NCT03343665 | Hodgkin Lymphom... | Nivolumab 40 mg... | 18 Years - 80 Years | St. Petersburg State Pavlov Medical University | |
| Treg Cells for AGVHD in Non-myeloablative UCB Transplant | NCT02118311 | Hematologic Mal... | T Regulatory ce... Fludarabine Cyclophosphamid... Total Body Irra... | 18 Years - 69 Years | Masonic Cancer Center, University of Minnesota | |
| PVAG-14 Pilot for Intermediate Stages Hodgkin Lymphoma | NCT00512980 | Hodgkin Lymphom... | prednisone vinblastine doxorubicin gemcitabine | 18 Years - 60 Years | University of Cologne | |
| Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT | NCT01220297 | Hematologic Dis... Acute-graft-ver... Leukemia Non-Hodgkin Lym... Hodgkin Lymphom... | Sirolimus Mycophenolate m... Carmustine Etoposide Cyclophosphamid... FTBI | 2 Years - 60 Years | Stanford University | |
| Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma | NCT01393106 | Hodgkin Lymphom... | Idelalisib | 12 Years - | Gilead Sciences | |
| Improving Exercise Capacity With Tailored Physical Activity in Lymphoma & Breast Cancer Patients Undergoing Tx | NCT03923504 | Hodgkin Lymphom... Non-hodgkin Lym... Lymphoma Breast Cancer | Physical Activi... Healthy Living ... | 18 Years - 85 Years | Virginia Commonwealth University | |
| Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma | NCT03478462 | Pediatric Solid... Pediatric Lymph... Pediatric Brain... DIPG Neuroblastoma Ewing Sarcoma Rhabdomyosarcom... Osteosarcoma | CLR 131 | 2 Years - 25 Years | Cellectar Biosciences, Inc. | |
| SARS-CoV-2 Donor-Recipient Immunity Transfer | NCT04666025 | Accelerated Pha... Acute Lymphobla... Acute Myeloid L... Chronic Lymphoc... Chronic Phase C... COVID-19 Infect... Hematopoietic a... Hodgkin Lymphom... Lymphoblastic L... Myelodysplastic... Myelofibrosis Myeloproliferat... Non-Hodgkin Lym... | Biospecimen Col... Diagnostic Labo... Electronic Heal... Questionnaire A... | 18 Years - | City of Hope Medical Center | |
| Phase II Trial to Evaluate an EBV-derived Dendritic Cell Vaccine in Autologous Stem Cell Transplant | NCT02115126 | Hodgkin Lymphom... Non-Hodgkin Lym... | LMP2A-loaded co... DUK-CPG-001 | 18 Years - | Duke University | |
| PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma | NCT05137886 | Hodgkin Lymphom... Relapse Refractory Hodg... | PD-1 inhibitor | 18 Years - 65 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| Haplo Peripheral Blood Sct In GVHD Prevention | NCT04473911 | GVHD AML ALL MDS MPN CMML Hodgkin Lymphom... Non Hodgkin Lym... Blood Stem Cell... Graft Vs Host D... Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Myeloproliferat... Chronic Myelomo... Chemosensitive ... | FLUDARABINE CYCLOPHOSPHAMID... TBI Melphalan Sirolimus Mycophenolate m... RGI-2001 CYCLOPHOSPHAMID... | 18 Years - 80 Years | Massachusetts General Hospital | |
| Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma | NCT02624258 | Hodgkin Lymphom... | CD19 RNA redire... | 18 Years - 24 Years | University of Pennsylvania | |
| Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma | NCT00722488 | Hematologic Mal... Multiple Myelom... Lymphoma Hodgkin Lymphom... | MLN4924 | 18 Years - | Millennium Pharmaceuticals, Inc. | |
| Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin Lymphoma | NCT02275598 | Hodgkin Lymphom... | Brentuximab ved... ABVD | 8 Years - 70 Years | University of Modena and Reggio Emilia | |
| Brentuximab for Newly Diagnosed Hodgkin Disease | NCT02398240 | Hodgkin Lymphom... | Brentuximab Ved... Doxorubicin Vincristine Rituximab | 1 Year - 29 Years | New York Medical College | |
| Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma | NCT00439361 | Hodgkin Lymphom... Lymphoma | Bortezomib Carboplatin Etoposide Ifosfamide Mesna | 16 Years - | M.D. Anderson Cancer Center | |
| Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies | NCT00013533 | Hodgkin Lymphom... Lymphocytic Leu... Mixed Cell Leuk... Myelodysplastic... Non Hodgkin's L... CML ALL AML Lymphoma | Stem cell trans... | 4 Years - 20 Years | National Institutes of Health Clinical Center (CC) | |
| Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant | NCT01244906 | Hematologic Neo... | Allogeneic Hema... | 18 Years - 75 Years | Northside Hospital, Inc. | |
| A Multi-centre Study of MBVD in Elderly and/or Cardiopathic Patients Affected by Hodgkin's Lymphoma (HL) | NCT01523847 | Hodgkin Lymphom... | MBVD (Myocet+BV... | 18 Years - | Fondazione Italiana Linfomi - ETS | |
| Lopinavir and Ritonavir in Improving Immune Response to Vaccines in Patients With Complete Remission Following A Bone Marrow Transplant for Hodgkin Lymphoma | NCT01165645 | Hodgkin Lymphom... Stage I Adult H... Stage II Adult ... Stage III Adult... Stage IV Adult ... | lopinavir ritonavir polymerase chai... flow cytometry enzyme-linked i... laboratory biom... | 18 Years - | Mayo Clinic | |
| A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma | NCT02572167 | Hodgkin Lymphom... | brentuximab ved... nivolumab | 18 Years - | Seagen Inc. | |
| Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant | NCT05031897 | Acute Lymphobla... Acute Myeloid L... Aplastic Anemia Chronic Lymphoc... Chronic Myelomo... Essential Throm... Hematopoietic a... Hodgkin Lymphom... Myelodysplastic... Myelofibrosis Myeloid Leukemi... Myeloid Neoplas... Non-Hodgkin Lym... Plasma Cell Mye... Polycythemia Ve... Small Lymphocyt... | Hematopoietic C... Mycophenolate M... Tacrolimus Cyclophosphamid... Total-Body Irra... Donor Lymphocyt... Fludarabine Melphalan | 18 Years - | Thomas Jefferson University | |
| Gonadal Toxicity in Women With Hodgkin Lymphoma | NCT01008735 | Hodgkin Lymphom... | 18 Years - 40 Years | Gruppo Italiano Studio Linfomi | ||
| A Longitudinal Assessment of Frailty in Young Adult Survivors of Childhood Cancer | NCT02256137 | Acute Lymphobla... Brain Tumor Hodgkin Lymphom... | 18 Years - 45 Years | St. Jude Children's Research Hospital | ||
| Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL) | NCT01657331 | Hodgkin Lymphom... Anaplastic Larg... | Brentuximab Ved... Bendamustine Neulasta | 18 Years - | Columbia University | |
| Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies | NCT01947140 | Lymphoid Malign... Multiple Myelom... Lymphoma Hodgkin Lymphom... Non-hodgkin Lym... | Pralatrexate Romidepsin | 18 Years - | Columbia University | |
| Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma | NCT05595447 | Hodgkin Lymphom... Refractory Hodg... Relapsed Hodgki... | Brentuximab Ved... | 15 Years - 90 Years | Hospital Regional de Alta Especialidad del Bajio | |
| ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells | NCT06090864 | Hodgkin Lymphom... Relapse Refractory | Chemotherapy Cell infusion | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma | NCT02432235 | Hodgkin Lymphom... Non-Hodgkin Lym... | Camidanlumab te... | 18 Years - | ADC Therapeutics S.A. | |
| Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | NCT02566304 | Acute Myeloid L... Acute Myeloid L... Aplastic Anemia Chronic Myelomo... Hodgkin Lymphom... Indolent Non-Ho... Malignant Neopl... Myelodysplastic... Myeloproliferat... Plasma Cell Mye... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Refractory Cyto... | Fludarabine Total-Body Irra... T Cell-Depleted... Cyclophosphamid... Peripheral Bloo... Allogeneic Hema... Tacrolimus Mycophenolate m... Laboratory Biom... | 18 Years - | Thomas Jefferson University | |
| AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies. | NCT06137144 | Lymphoma Non-Hodgkin Hodgkin Lymphom... | AZD3470 | 15 Years - 130 Years | AstraZeneca | |
| The Use of FDG-PET in Patient With Hodgkin Lymphoma: a Population Based Study From Northern Italy | NCT01248000 | Histologically ... | FDG-PET | 18 Years - | Gruppo Italiano Studio Linfomi | |
| Dose-dense ABVD First Line Therapy in Early Stage Unfavorable Hodgkin's Lymphoma | NCT02247869 | Hodgkin Lymphom... | dose dense ABVD | 18 Years - 70 Years | Fondazione Italiana Linfomi - ETS | |
| Improving Exercise Capacity With Tailored Physical Activity in Lymphoma & Breast Cancer Patients Undergoing Tx | NCT03923504 | Hodgkin Lymphom... Non-hodgkin Lym... Lymphoma Breast Cancer | Physical Activi... Healthy Living ... | 18 Years - 85 Years | Virginia Commonwealth University | |
| PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma | NCT05922904 | Hodgkin Lymphom... | Brentuximab ved... Doxorubicin Hyd... Pembrolizumab Dacarbazine | 18 Years - | M.D. Anderson Cancer Center | |
| Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma | NCT01251107 | Hodgkin Lymphom... | Bleomycin Etoposide Doxorubicin Cyclophosphamid... Vincristine Procarbazine Prednisone Doxorubicin Bleomycin Vinblastine Dacarbazine | 17 Years - 60 Years | Fondazione Michelangelo | |
| Use of Zarzio® in Post-autologous Stem Cell Transplantation Procedure | NCT03323541 | Multiple Myelom... Non-hodgkin Lym... Hodgkin Lymphom... | Filgrastim Pref... | 18 Years - | University Hospital, Brest | |
| Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma | NCT03618550 | Hodgkin Lymphom... Relapsed or Ref... | pembrolizumab gemcitabine vinorelbine liposomal doxor... Stem cell mobil... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma | NCT03580408 | Hodgkin Lymphom... Coexisting Medi... | Nivolumab Vinblastin | 61 Years - | The Lymphoma Academic Research Organisation | |
| A Multi-center, Non-randomized, Open-label Phase II Clinical Study on the Treatment of Newly Diagnosed Advanced Hodgkin's Lymphoma With PD-1 Antibody (Tislelizumab) Combined With AVD Regimen (Doxorubicin, Vindesine, Dacarbazine) Under the Guidance of PET/CT | NCT04843267 | Hodgkin Lymphom... Chemotherapy Ef... | Tislelizumab | 18 Years - 80 Years | Sun Yat-sen University | |
| Positron Emission Tomography (PET)-Adapted Chemotherapy In Advanced Hodgkin Lymphoma (HL) | NCT00795613 | HODGKIN LYMPHOM... | ESCALATED BEACO... CONVENTIONAL AB... | 18 Years - 60 Years | Ospedale Santa Croce-Carle Cuneo | |
| Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma | NCT01534078 | Hodgkin Lymphom... | Brentuximab Ved... Adriamycin, vin... | 18 Years - | Massachusetts General Hospital | |
| Improving Exercise Capacity With a Tailored Physical Activity Intervention | NCT05595577 | Non Hodgkin Lym... Heart; Function... Hodgkin Lymphom... Quality of Life | Exercise with T... Cardiopulmonary... MRI scan Quality of Life... Cognitive and B... Blood draws | 18 Years - 85 Years | Wake Forest University Health Sciences | |
| Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | NCT05476770 | Hematologic Mal... AML ALL BPDCN MDS Lymphoblastic L... Lymphoma, B-Cel... Lymphoma, T-Cel... Hodgkin Lymphom... Mixed Phenotype... Acute Undiffere... | Tagraxofusp Fludarabine Cytarabine Dexamethasone Vincristine Azacitidine Methotrexate Cytarabine IT Hydrocortisone | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Obstructive Sleep Apnea in Survivors of Hodgkin Lymphoma Treated With Thoracic Radiation | NCT03361020 | Obstructive Sle... Hodgkin Lymphom... | 18 Years - | St. Jude Children's Research Hospital | ||
| Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies | NCT01947140 | Lymphoid Malign... Multiple Myelom... Lymphoma Hodgkin Lymphom... Non-hodgkin Lym... | Pralatrexate Romidepsin | 18 Years - | Columbia University | |
| HD18 for Advanced Stages in Hodgkins Lymphoma | NCT00515554 | Hodgkins Lympho... | Rituximab BEACOPP escalat... | 18 Years - 60 Years | University of Cologne | |
| CBT on Fatigue in Survivors of Hodgkin Lymphoma | NCT03968250 | Hodgkin Lymphom... Fatigue | Cognitive Behav... | 18 Years - | University of Leipzig | |
| VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies | NCT03885947 | Hematological M... Acute Leukemia ... Acute Lymphobla... Myelodysplastic... Non-Hodgkin Lym... Hodgkin Lymphom... | Cord blood stem... Valproic Acid Fludarabine cytoxan Thiotepa TBI | 18 Years - 65 Years | Icahn School of Medicine at Mount Sinai | |
| Dose-dense ABVD First Line Therapy in Early Stage Unfavorable Hodgkin's Lymphoma | NCT02247869 | Hodgkin Lymphom... | dose dense ABVD | 18 Years - 70 Years | Fondazione Italiana Linfomi - ETS | |
| Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases | NCT02145039 | Acute Leukemias Burkitt's Lymph... Chronic Myeloge... | Fludarabine Cyclophosphamid... Total Body Irra... Haploidentical ... | - 74 Years | Masonic Cancer Center, University of Minnesota | |
| Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study | NCT05972577 | Acute Lymphobla... Acute Myeloid L... Aplastic Anemia Chronic Lymphoc... Chronic Myeloge... Hematopoietic a... Hodgkin Lymphom... Myelodysplastic... Myelofibrosis Myeloproliferat... Non-Hodgkin Lym... Plasma Cell Mye... | Health Promotio... Medical Device ... Quality-of-Life... Questionnaire A... | 60 Years - | Ohio State University Comprehensive Cancer Center | |
| Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT) | NCT02169505 | Lymphoma | Brentuximab Ved... | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer | NCT00602693 | Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic... | umbilical cord ... Allopurinol fludarabine pho... Cyclophosphamid... Total body irra... Treg infusion Sirolimus | 18 Years - 75 Years | Masonic Cancer Center, University of Minnesota | |
| HD17 for Intermediate Stage Hodgkin Lymphoma | NCT01356680 | Hodgkin Lymphom... | BEACOPPescalate... ABVD (Adriamyci... 30Gy IF-RT (Inv... 30Gy IN-RT (Inv... | 18 Years - 60 Years | University of Cologne | |
| A Study of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma | NCT03505996 | Hodgkin Lymphom... | CS1001 | 18 Years - 75 Years | CStone Pharmaceuticals | |
| Immunogenicity of COVID-19 Vaccination in Autologous HSCT or CAR-T Cells Recipients | NCT05597761 | COVID-19 Non Hodgkin Lym... Hodgkin Lymphom... | 18 Years - | University of Cologne | ||
| Whole-body Diffusion-weighted Magnetic Resonance Imaging for Staging and Treatment Prediction of Lymphoma | NCT01231269 | Lymphoma Hodgkin Lymphom... Non-Hodgkin Lym... | MRI | - | Universitaire Ziekenhuizen KU Leuven | |
| Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | NCT02665650 | Hodgkin Lymphom... | AFM13 Pembrolizumab | 18 Years - | Affimed GmbH | |
| Lymphoma RadVax LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS | NCT03495713 | Hodgkin Lymphom... | Nivolumab | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Understanding the Risk of Blood Clots and Bleeding in Patients With Hematological Malignancies, HAT Study | NCT05053100 | Acute Leukemia Deep Vein Throm... Hematopoietic a... Hodgkin Lymphom... Myeloproliferat... Non-Hodgkin Lym... Plasma Cell Mye... Thrombocytopeni... | Biospecimen Col... Electronic Heal... | 18 Years - | Mayo Clinic | |
| A Longitudinal Assessment of Frailty in Young Adult Survivors of Childhood Cancer | NCT02256137 | Acute Lymphobla... Brain Tumor Hodgkin Lymphom... | 18 Years - 45 Years | St. Jude Children's Research Hospital | ||
| Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation | NCT01634217 | Acute Myelogeno... Acute Lymphocyt... Chronic Myeloge... Non-Hodgkin Lym... Hodgkin Lymphom... Chronic Lymphoc... Multiple Myelom... Myelodysplastic... | iTreg | 18 Years - 75 Years | Masonic Cancer Center, University of Minnesota | |
| BV After Allogeneic Hematopoietic Stem Cell Transplantation | NCT03540849 | Hodgkin Lymphom... | Brentuximab Ved... | 18 Years - 65 Years | University Hospital, Caen | |
| Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD | NCT02298283 | Hodgkin Lymphom... | brentuximab ved... Cyclophosphamid... Adriamycin Oncovin Bleomycin Etoposide Procarbazine Prednisone G-CSF 30 Grays | 18 Years - 65 Years | The Lymphoma Academic Research Organisation | |
| Proton Therapy for Hodgkin Lymphoma | NCT00850200 | Hodgkin Lymphom... | Proton Radiatio... Conventional Ph... Intensity Modul... | 6 Years - | University of Florida | |
| Lung Screening in People Cured of Hodgkin Lymphoma | NCT04986189 | Hodgkin Lymphom... Lung Cancer | Low dose CT tho... | 18 Years - 80 Years | The Christie NHS Foundation Trust | |
| Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma | NCT01217229 | Hodgkin Lymphom... | PLX3397 | 18 Years - | Daiichi Sankyo | |
| Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients | NCT05974410 | Glioblastoma Squamous Cell C... Hodgkin Lymphom... Non-hodgkin Lym... Breast Cancer Prostate Cancer Gastric Cancer Ovarian Cancer Acute Leukemia Pancreatic Canc... Spindle Cell Sa... Cancer Tumor, Solid Tumor, Brain | AVM0703 Hydrocortisone Proton pump inh... | - | AVM Biotechnology Inc | |
| Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | NCT05476770 | Hematologic Mal... AML ALL BPDCN MDS Lymphoblastic L... Lymphoma, B-Cel... Lymphoma, T-Cel... Hodgkin Lymphom... Mixed Phenotype... Acute Undiffere... | Tagraxofusp Fludarabine Cytarabine Dexamethasone Vincristine Azacitidine Methotrexate Cytarabine IT Hydrocortisone | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
